Treatment of cells with interferon-γ leads to the replacement of the constitutive catalytic
proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i) …

The proteasome is responsible for mediating intracellular protein degradation and
regulating cellular function with impact on tumor and immune effector cell biology. The …

Introduction: The ubiquitin–proteasome system is responsible for maintaining protein
homeostasis and regulating a variety of cellular processes. The constitutive proteasome is …

Mammalian genomes encode seven catalytic proteasome subunits, namely, β1c, β2c, β5c
(assembled into constitutive 20S proteasome core particles), β1i, β2i, β5i (incorporated into …

Selective inhibitors for the human immunoproteasome LMP7 (β5i) subunit over the
constitutive proteasome hold promise for the treatment of autoimmune and inflammatory …

The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all
eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for …

Proteasome inhibitors are emerging as effective drugs for the treatment of multiple myeloma
and possibly certain subtypes of non-Hodgkin's lymphoma. Bortezomib (Velcade) is the first …

Proteasomes are therapeutic targets for various cancers and autoimmune diseases.
Constitutively expressed proteasomes have three active sites, β1c, β2c, and β5c. Lymphoid …

The immunoproteasome is expressed in cells of hematopoietic origin and is induced during
inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been …

Immunoproteasome is a variant of proteasome with structural differences in 20S subunits
optimizing them for the production of antigenic peptides with higher binding affinity to major …